



MINUTES

Utah Department of Health
Pharmacy and Therapeutics Committee

Thursday, June 15, 2017
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 128

Committee Members Present:

Clinton Sheffield, MD
Clayton Grace, RPh
Keith Tolman, MD

Susan Siegfried, MD
Bryan Larson, PharmD

Committee Members Excused:

Elizabeth Young, PharmD
Abril Atherton, PharmD
Jake Jones, MD

Dept. of Health/Div. of Health Care Financing Staff Present:

Sue Leong, RPh., Pharmacy Director
Merelynn Berrett, RN
Heather Santacruz, RN
Alyssa Pitts, RN

Andrea Rico, CPhT
Robyn Seely, PharmD

University of Utah Drug Regimen Review Center Staff Present:

Valerie Gonzales, PharmD

Other Individuals Present:

Jennifer Lauper, Bristol Myers Squibb
Blake Bolinger, Bristol Myers Squibb
Joshua Whittington, Bristol Myers Squibb
Joanita Lake, U of U
Scott Clegg, Lilly
Cody Ball, SelectHealth
Roy Lindfield, Sunovion
Lori Howarth, Bayer

Monica Saleh, Shire
Joanne LaFleur, U of U
Rob Bingham, Shire
John Sandstream, Shire
Charissa Anne, J&J
Jean Rutter, Quintiles
Elena Martinez, U of U

Meeting conducted by: Committee Chair

1. **Welcome & Housekeeping:** Clinton Sheffield opened the meeting and reminded everyone to sign the rosters. Keith Tolman nominated Clinton Sheffield to remain as the P&T chair for the 2018 year. Clayton Grace seconded the motion. Unanimous approval.
2. **Review and Approval of May Minutes:** Clinton Sheffield made a motion to approve the minutes from May. Unanimous approval.
3. **Drug Utilization Review (DUR) Board update:** The DUR Board met last week

to discuss Entresto. Robyn Seely stated that the clinical PA criteria has been removed. However, one criterion trial and/or failure of an ACEI/ARB would remain which will result in an automatic prior authorization at point of sale if the member has met the criterion. DURB also reviewed long acting insulins and opted not to implement any prior authorization criteria.

4. **Parathyroid Hormone Analogs:** Valerie Gonzales presented a review of Parathyroid Hormone Analogs. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data
5. **Public Comment:** Monica Saleh, medical liaison for Shire Pharmaceuticals presented clinical information pertaining to Natpara.
6. **Other State Report:** Bryan Larson reported PDL listings for agents in this class in other States' Medicaid programs.
7. **Committee Discussion:** Bryan Larson made a motion to rename the vitamin D analogs to Parathyroid agents and move Natpara under the new label. Motion abandoned. Bryan Larson motioned to have Natpara removed from the preferred drug list. Clinton Sheffield seconded. Unanimous approval. Abaloparatide and Teriparatide will remain non-preferred on the Utah PDL.
8. **Public Meeting Adjourned:** Bryan Larson motioned to close the meeting. Clinton Sheffield seconded the motion. Unanimous Approval.
9. **Next meeting is scheduled for** August 17, 2017 Long-Acting Anticholinergic, Beta-2 Agonist Combination Inhalers.

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>